Ischaemic heart disease patients presenting for PCI Circulatory System Ischaemic heart disease
Conditions
Interventions
Patients will have blood samples for biomarkers taken at 0, 4, 6 and 24 hours following stenting, and receive a telephone call at 30 days and one year following stenting to assess for adverse outcomes
Sponsors
Randox Laboratories (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged over 18 at enrolment 2. Undergoing Percutaneous Coronary Intervention (PCI) for chronic stable angina or as part of staged procedure following acute coronary syndrome (ACS)/myocardial infarction (MI) (index event >14 days previously)
Exclusion criteria
Exclusion criteria: 1. Terminal malignancy 2. Inability to give informed consent due to impaired mental capacity 3. ACS/chest pain at admission/MI within last 14 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post procedure biomarker elevation diagnostic for Type 4a myocardial infarction | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Major Adverse Cardiac Events (MACE) at 30 days and 1 year 1.1. Myocardial infarction 1.2. Stroke 1.3. Target vessel revascularisation 1.4. Heart failure hospitalisation 1.5. Death | — |
Countries
United Kingdom
Outcome results
None listed